We want to share a reminder with all job seekers and candidates regarding the persistence of recruiting fraud. Please read a message about recruiting fraud and steps you can take to protect yourself here: https://lnkd.in/e8m6bKFw
Sarepta Therapeutics
Biotechnology Research
Cambridge, MA 106,716 followers
Dragging Tomorrow Into Today.
About us
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a global biotechnology company on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For information on our Community Guidelines, please visit sarepta.com/community-guidelines. We want to share a reminder with all job seekers and candidates regarding the persistence of recruiting fraud. Please read a message about recruiting fraud and steps you can take to protect yourself here: https://www.sarepta.com/recruiting-fraud
- Website
-
http://www.sarepta.com
External link for Sarepta Therapeutics
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
Locations
-
Primary
215 First Street
Cambridge, MA 02142, US
-
100 Federal St
Andover, Massachusetts 01810, US
Employees at Sarepta Therapeutics
Updates
-
Today is the last day to apply for our 2024 LGMD grant program, an initiative that awards funds to organizations that can help drive LGMD awareness and education. Apply here: https://lnkd.in/e5272QSX
-
-
As Sarepta’s summer internship program continues, interns recently had the opportunity to gather and connect with our Executive Vice President, Head of R&D and Chief Scientific Officer Louise Rodino-Klapac, Ph.D. Interns called in from our different locations, while our Columbus-based interns met in person with Dr. Rodino-Klapac at our Genetic Therapies Center of Excellence (GTCOE). They learned more about her journey to Sarepta and took a deep dive into the discovery, pre-clinical and clinical development supporting Sarepta’s pipeline of genetic medicines. Columbus is just one of the five locations hosting a total of 26 interns this summer. Hard to believe summer is nearly halfway over already!
-
-
At Sarepta, we have a quarterly tradition of celebrating colleagues who demonstrate an exceptional commitment to our cultural #values. The most recent recipient of our quarterly InGENEious Award is Ken Murray, vice president, Quality Control. His scientific and mathematical expertise ensures Sarepta’s manufacturing process pairs the highest level of quality with robust efficiencies, because we understand that every minute counts for patients. We thank you for your unwavering dedication to the Sarepta mission. Congratulations, Ken! #OneSarepta
-
-
Still thinking about the great conversations that were had at Parent Project Muscular Dystrophy's 30th Annual Conference. Spending time with members of the #duchenne community always leaves us feeling energized and inspired. Thanks to all who made it a special gathering!
-
-
As we close out #PrideMonth, we’re highlighting Sarepta Pride, our Employee Resource Group (ERG) for LGBTQIA+ employees and allies. Pride is comprised of colleagues from across our organization, and today we’re introducing Pride Co-Lead Jean Olivo, MLIS. Swipe to read more about how Jean’s involvement with Pride has contributed to his experience at Sarepta. Learn his perspective on how ERGs like Pride support the advancement of Sarepta’s mission and how celebrating our differences in the workplace can help people grow both personally and professionally. #Pride
-
We are the leaders in providing treatment options for the Duchenne community, and we remain steadfastly committed to furthering progress for every person living with Duchenne. We’re proud to be a Star sponsor of Parent Project Muscular Dystrophy's Annual Conference this year.
-
-
Our head of R&D and Chief Scientific Officer, Louise Rodino-Klapac, Ph.D, on today’s news regarding advances in the treatment of Duchenne muscular dystrophy: